Ifetroban

Drug Profile

Ifetroban

Alternative Names: BMS 18029; BMS 180291; BMS 180291A; Boxaban; CPI 211; Hepatoren; Portaban; VasculanTM

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cumberland Pharmaceuticals
  • Class Antiplatelets; Heterocyclic bicyclo compounds; Oxazoles; Small molecules
  • Mechanism of Action Prostaglandin receptor antagonists; Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Hepatorenal syndrome; Portal hypertension; Systemic scleroderma
  • Discontinued Coronary thrombosis; Peripheral vascular disorders; Thrombosis

Most Recent Events

  • 14 Sep 2016 Phase-II clinical trials in Portal hypertension in USA (PO)
  • 14 Sep 2016 The US FDA approves IND application for ifetroban in Portal hypertension
  • 13 Jun 2016 Cumberland Pharmaceuticals plans a phase II trial in Portal hypertension (in cirrhotic patients) in USA (NCT02802228)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top